Replies to post #10180 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

BesaoT35, the CEO, Art Przybyl stated they are targeting 50% of the existing market share. They will enough product API,etc.. to meet that demand.

What kind of sales would Corticotropin expect to get?
If they get 50 % market share, it will give them at least an additional $200 million in Free Cash Flow.

The CEO believes the odds very are good. Unlike a new drug this drug was previously approved and qualifies under an sNDA application. The same steps Acthar got approved.

Analyst covering MNK were estimating sales drop of

$260 million in 2020,
$350 million in 2021,
$90 million in 2022,
$30 million in 2023.

No doubt much of this relates to Acthar losing market share.

CEO was non-commital as to announcements. But a PDUFA will be issued most likely for July, assuming they file in March.

ANIp has a larger strategy for growing sales beyond the currenttarget of 50% maret share.

Fpor more info on ANIP's strategy check out the following,

Why ANI Pharmaceuticals Considers Corticotropin Gel Its Blockbuster Drug